Welcome to our dedicated page for Absci news (Ticker: ABSI), a resource for investors and traders seeking the latest updates and insights on Absci stock.
Absci Corporation (Nasdaq: ABSI) is a clinical-stage biopharmaceutical and biotechnology company that frequently issues news related to its generative AI-driven drug discovery platform and internal pipeline of biologic therapeutics. News coverage for Absci often centers on developments in its lead AI-designed antibody programs, platform collaborations, and corporate updates that are relevant to investors and the broader life sciences community.
A major focus of recent Absci news is ABS-201™, an anti-prolactin receptor (PRLR) antibody being developed for androgenetic alopecia and investigated for endometriosis. Press releases have described preclinical human ex vivo data on hair growth, the design and initiation of the Phase 1/2a HEADLINE trial in androgenetic alopecia, and plans for Phase 2 development in endometriosis. Updates also highlight scientific advisory board appointments, key opinion leader seminars, and partnerships aimed at elevating patient perspectives in hair loss research.
Investors following ABSI news can also expect announcements on pipeline progress for programs such as ABS-101, ABS-301, and ABS-501, as well as drug creation partnerships with pharmaceutical, biotech, technology, and academic organizations. Absci has reported collaborations with cloud and hardware providers to support its AI Drug Creation platform, along with participation in healthcare and biotech investor conferences and major industry events.
This news feed aggregates Absci’s press releases and third-party coverage, including items on clinical trial milestones, scientific data presentations, financing and capital markets activity, and corporate governance changes. Readers interested in ABSI can use this page to monitor how Absci’s AI-enabled platform, internal therapeutic programs, and partnerships evolve over time and to track key events that may shape the company’s scientific and business trajectory.
Absci Corporation (Nasdaq: ABSI) reported its Q1 2022 financial results, highlighting significant advancements in drug discovery technology and collaborations. The company entered a research collaboration with Merck with potential $610 million in payments. Absci unveiled breakthroughs in machine learning for antibody affinity predictions and developed a scoring model for antibody 'naturalness.' Financially, cash reserves stood at $226 million, funding operations through 2024, though net loss rose to $29.5 million. Absci projects 60% growth with at least eight new Active Programs in 2022.
Absci Corporation (Nasdaq: ABSI) announced its participation in the BofA Securities 2022 Healthcare Conference in Las Vegas, scheduled for May 11 at 5:20 p.m. PT. The company leverages deep learning AI and synthetic biology to enhance protein therapeutic potential. Absci's Integrated Drug Creation™ Platform identifies novel drug targets and optimizes biotherapeutic candidates efficiently. Investors can access the live and archived presentation via the company’s investor relations website.
Absci Corporation (Nasdaq: ABSI) has opened the Absci AI Research Lab (AAIR Lab) in Manhattan's Carnegie Hall Tower, enhancing its in-silico drug discovery capabilities. This strategic expansion follows Absci's recent advancements in machine learning for antibody optimization and its collaboration with NVIDIA. The lab aims to accelerate therapeutic protein design and support the Denovium™ Engine AI platform. CEO Sean McClain highlighted the significance of the location and the talent pool, emphasizing the company's vision for innovative drug development.
Absci Corporation (Nasdaq: ABSI) reported its financial results for Q4 and the full year 2021, highlighting a significant increase in R&D and administrative expenses. Revenue for Q4 was $1.5 million, down from $2.7 million in Q4 2020. For the full year, revenue remained stable at $4.8 million. R&D expenses surged to $44.6 million from $11.4 million year-over-year, contributing to a net loss of $101 million for 2021. Despite these challenges, Absci made strides by initiating collaborations with Merck and NVIDIA and expects to launch eight new Active Programs in 2022.
Absci Corporation (Nasdaq: ABSI) announced advancements in its in-silico drug discovery technology during a presentation at NVIDIA GTC. The company focuses on machine learning models for therapeutic antibodies, aiming for a seamless pipeline from target identification to drug candidate creation. Breakthroughs include a model predicting antibody target affinity and a scoring system for the 'naturalness' of antibody variants, enhancing their developability. Collaborating with NVIDIA aims to further accelerate this innovative platform, with potential implications for the drug discovery industry.
Absci Corporation has appointed Andreas Busch, PhD, to its Board of Directors, enhancing its leadership in drug discovery.
Dr. Busch brings over 20 years of experience, previously serving as EVP and Chief Scientific Officer at Shire and Head of Drug Discovery at Bayer.
His expertise is expected to bolster Absci's efforts in in-silico design of therapeutic proteins as the company advances its unique Integrated Drug Creation™ Platform.
Absci Corporation (Nasdaq: ABSI) announced that Lead AI Scientist Joshua Meier will present at NVIDIA GTC on March 22, 2022, at 1:00 p.m. PT. The session focuses on leveraging deep learning and synthetic biology for drug and target discovery. Attendees can register for free to join the virtual presentation at NVIDIA's official site.
Absci aims to expand the therapeutic potential of proteins using its Integrated Drug Creation™ Platform, partnering with biotech and pharma innovators to develop the next generation of protein-based drugs.
Absci Corporation (Nasdaq: ABSI) announced that CEO Sean McClain will participate in the Synthetic Biology Enabling Drug Discovery Panel at the Cowen 42nd Annual Health Care Conference. The event is set for March 8, 2022, from 12:30-1:30 p.m. Pacific Time / 3:30-4:30 p.m. Eastern Time. A live and archived webcast will be available on the company’s investor relations website.
Absci leverages deep learning AI and synthetic biology in drug discovery, aiming to advance the therapeutic potential of proteins.
Absci Corporation (Nasdaq: ABSI), a pioneer in drug and target discovery utilizing deep learning AI, announced its participation in two upcoming virtual investor conferences. The Truist Life Sciences AI Symposium will feature a panel discussion on March 1, 2022, at 7:10 a.m. PT, while the Cowen 42nd Annual Health Care Conference will include a fireside chat on March 7, 2022, at 9:50 a.m. PT. Interested attendees can access these events through the provided links. These engagements highlight Absci's commitment to expanding the therapeutic potential of proteins and facilitating drug development.
Absci Corporation (Nasdaq: ABSI) will participate virtually in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 15, 2022, at 8:30 a.m. Pacific Time. The company specializes in drug and target discovery by leveraging deep learning AI and synthetic biology, aiming to enhance the therapeutic potential of proteins. Absci's Integrated Drug Creation™ Platform allows the identification of novel drug targets and the discovery of optimal biotherapeutic candidates in a streamlined process. For more information, visit www.absci.com.